California scientists have made a major breakthrough in the treatment of cancer. They’ve found a ‘kill switch’. Which is successful in killing cancer cells. ‘California experts at the UC Davis Comprehensive Cancer Center in Sacramento say they have identified a protein that mimics a receptor that can be designed to kill cancer cells. These are CD95 receptors also known as Fas. These are called death receptors. These protein receptors reside on the cell membrane. When cancer cells become active and release signals, these receptors kill them or they themselves die after coming in contact with the receptors."text-align: justify;">How will the therapy be given?
Researchers have named it CAR T-cell therapy. In which T cells will be collected from the patient’s blood and inserted into human genes in the lab. After which receptors called chimeric antigen receptors (CAR) are formed in the body. After that these cells are put back into the blood circulation of the patient’s body. “We have found the most important epitope for cytotoxic Fas signaling as well as CAR T-cell bystander anti-tumor function,” said Jogender Tushir-Singh, associate professor in the Department of Medical Microbiology and Immunology and senior author of the research. p style="text-align: justify;">How effective is this therapy
So far the therapy has shown promising efficacy against serous cancers, leukemia and other blood cancers. According to scientists, this will be successful in the treatment of solid tumors like breast cancer, lung and intestinal cancer. However, the team hopes that therapy may be developed to target solid cancers as well in the near future.
Modulating Fas Ovarian Cancer
The team said in its statement that modulating Fas could also enhance the benefits of chimeric antigen receptor (CAR) T-cell therapy for solid tumors such as ovarian cancer. At first we were not successful in identifying the receptor but when We did further research and when we identified the epitope, we saw that it showed a very positive response in treating tumorous cancers.